Report Analysis and Forecast on Myasthenia Gravis - Pipeline Review, H2 2016
Myasthenia Gravis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Myasthenia Gravis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.
To view the table of contents and know more details please visit Myasthenia Gravis - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
- The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis
- The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis
Reasons to buy
- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Achillion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. Alpha Cancer Technologies Inc. arGEN-X BV Biokine Therapeutics Ltd. BioMarin Pharmaceutical Inc. CuraVac, Inc. GlaxoSmithKline Plc Grifols, S.A. HanAll Biopharma Co., Ltd. Karus Therapeutics Limited Millennium Pharmaceuticals Inc Neurotune AG Novartis AG Pfizer Inc. ReceptoPharm, Inc. Regenesance BV Shire Plc Toleranzia AB
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 01:07
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home